View Older Stories View More Recent Stories

Nov 5, 2024 08:00AM Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
Oct 31, 2024 04:02PM Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct 28, 2024 04:05PM Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
Oct 24, 2024 04:06PM Ardelyx (ARDX) Reports Additional Data Supporting First-In-Class XPHOZAH
Oct 24, 2024 04:05PM Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
Oct 22, 2024 04:06PM Ardelyx (ARDX) Announces Launch of Gut Matters
Oct 22, 2024 04:05PM Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
Oct 21, 2024 04:05PM Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
Oct 17, 2024 08:00AM Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
Oct 15, 2024 08:00AM Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
Oct 9, 2024 08:05AM Ardelyx (ARDX) Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
Oct 9, 2024 08:05AM Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
Sep 5, 2024 08:00AM Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
Aug 8, 2024 08:01AM Ardelyx (ARDX) Appoints Eric Foster as Chief Commercial Officer
Aug 8, 2024 08:00AM Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
Aug 1, 2024 04:01PM Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
Jul 31, 2024 08:02AM Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
Jul 18, 2024 08:00AM Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
Jul 17, 2024 05:10PM Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
Jul 2, 2024 07:02AM Ardelyx (ARDX) to Not File for TDAPA
Jul 2, 2024 07:00AM To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
Jun 28, 2024 08:17AM Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
May 30, 2024 04:02PM Ardelyx, Inc. Reports Employment Inducement Grants
May 22, 2024 08:02AM Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
May 21, 2024 08:02AM Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 16, 2024 08:01AM Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
May 14, 2024 04:02PM Ardelyx, Inc. Reports Employment Inducement Grants
May 7, 2024 08:01AM Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
May 2, 2024 04:02PM Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
May 1, 2024 08:00AM Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
Apr 18, 2024 08:00AM Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
Mar 28, 2024 04:05PM Ardelyx, Inc. Reports Employment Inducement Grants
Mar 25, 2024 08:00AM Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
Mar 12, 2024 04:35PM Ardelyx, Inc. Reports Employment Inducement Grants
Feb 27, 2024 08:00AM Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
Feb 22, 2024 04:01PM Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Feb 1, 2024 08:00AM Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Jan 12, 2024 07:56AM Ardelyx, Inc. Reports Employment Inducement Grants
Jan 8, 2024 08:05AM Ardelyx (ARDX) Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
Jan 8, 2024 08:00AM Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
Jan 3, 2024 08:03AM Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
Dec 20, 2023 08:00AM Ardelyx, Inc. Reports Employment Inducement Grants
Nov 21, 2023 04:02PM Ardelyx, Inc. Reports Employment Inducement Grants
Nov 21, 2023 08:01AM Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
Nov 15, 2023 04:02PM Ardelyx (ARDX) Granted FDA Orphan Drug Designation for XPHOZAH
Nov 15, 2023 04:02PM XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
Nov 13, 2023 04:03PM Ardelyx (ARDX) Announces Resignation of Geoffrey Block from Board
Nov 13, 2023 04:02PM Ardelyx Announces Departure of Board Member
Nov 10, 2023 08:05AM Ardelyx to Participate at the Jefferies London Healthcare Conference
Nov 6, 2023 08:02AM Ardelyx (ARDX) Announces XPHOZAH now Available in the US
View More Recent Stories View Older Stories